EUVIMEDEUVIMED entdecken
Kohortenstudie

Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study

Shunbing Lu, Qingqian Wei, Juan Ma, Jun Zhuang, Xueshang Su, Yunshun Lu, Ziming Zhang, Yutong Liang, Jintian Hu

Aesthetic Surgery Journal · 23.04.2026

DOI: 10.1093/asj/sjag076 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 23.04.2026. Verfasst von Shunbing Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cosmetic Injection Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chi…. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ptosis, the drooping of the upper eyelid caused by levator palpebrae superioris dysfunction, can impair vision and quality of life. Standard treatments include surgery, whereas botulinum toxin injections have shown potential noninvasive benefits.

Objectives

The aim of this study was to evaluate the efficacy and safety of orbicularis oculi muscle botulinum toxin injection vs levator palpebrae superioris muscle shortening surgery for ptosis.

Methods

Thirty-six patients with levator palpebrae superioris muscle weakness were assigned to an experimental group receiving botulinum toxin injection or a control group undergoing traditional surgery. Primary outcomes were palpebral fissure height, visual function, and patient satisfaction; secondary outcomes were adverse reactions and recovery time.

Results

The experimental group showed greater improvement in palpebral fissure height (3.5 mm vs 1.7 mm) and visual function than the control group. Satisfaction was higher, mainly owing to the noninvasive procedure and shorter recovery. Adverse reactions were less frequent, with fewer complications such as scarring.

Conclusions

Botulinum toxin injection may be a minimally invasive option for selected patients, particularly those with mild dysfunction or wishing to avoid surgery. It improved eyelid height and visual function, reduced side effects, and accelerated recovery. Further studies should assess long-term effectiveness. Level of Evidence: 3 (Therapeutic)

Autor:innen und Institutionen

  • Department of Cosmetic Injection Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Plastic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
  • First People's Hospital of Lincang City, Yunnan Province, China.

Zitieren

APA

Lu, S., Wei, Q., Ma, J., Zhuang, J., Su, X., Lu, Y., Zhang, Z., Liang, Y., & Hu, J. (2026). Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjag076

Vancouver

Lu S, Wei Q, Ma J, Zhuang J, Su X, Lu Y, et al. Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study. Aesthetic Surgery Journal. 2026. doi:10.1093/asj/sjag076

BibTeX
@article{Lu2026,
  author = {Lu, Shunbing and Wei, Qingqian and Ma, Juan and Zhuang, Jun and Su, Xueshang and Lu, Yunshun and Zhang, Ziming and Liang, Yutong and Hu, Jintian},
  title = {Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study},
  journal = {Aesthetic Surgery Journal},
  year = {2026},
  doi = {10.1093/asj/sjag076}
}
Kostenlos starten →